Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Omeros

Nasdaq:OMER
Snowflake Description

High growth potential with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OMER
Nasdaq
$662M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. The last earnings update was 32 days ago. More info.


Add to Portfolio Compare Print
  • Omeros has significant price volatility in the past 3 months.
OMER Share Price and Events
7 Day Returns
10%
NasdaqGM:OMER
4.1%
US Pharmaceuticals
-4.1%
US Market
1 Year Returns
-34.1%
NasdaqGM:OMER
-7%
US Pharmaceuticals
-14.9%
US Market
OMER Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Omeros (OMER) 10% -38.1% -8.7% -34.1% -25.9% -50.3%
US Pharmaceuticals 4.1% -8.7% -12.1% -7% 4.7% 0.6%
US Market -4.1% -19.1% -23.4% -14.9% 3.5% 14.5%
1 Year Return vs Industry and Market
  • OMER underperformed the Pharmaceuticals industry which returned -7% over the past year.
  • OMER underperformed the Market in United States of America which returned -14.9% over the past year.
Price Volatility
OMER
Industry
5yr Volatility vs Market

Value

 Is Omeros undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Omeros is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Omeros has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Omeros. This is due to cash flow or dividend data being unavailable. The share price is $12.21.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Omeros's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Omeros's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:OMER PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.71
NasdaqGM:OMER Share Price ** NasdaqGM (2020-04-02) in USD $12.21
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 19.88x
United States of America Market PE Ratio Median Figure of 2,944 Publicly-Listed Companies 12.5x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Omeros.

NasdaqGM:OMER PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:OMER Share Price ÷ EPS (both in USD)

= 12.21 ÷ -1.71

-7.16x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Omeros is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Omeros is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Omeros's expected growth come at a high price?
Raw Data
NasdaqGM:OMER PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.16x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
45.5%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.88x
United States of America Market PEG Ratio Median Figure of 2,008 Publicly-Listed Companies 0.91x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Omeros, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Omeros's assets?
Raw Data
NasdaqGM:OMER PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-2.01
NasdaqGM:OMER Share Price * NasdaqGM (2020-04-02) in USD $12.21
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 2.41x
United States of America Market PB Ratio Median Figure of 5,142 Publicly-Listed Companies 1.22x
NasdaqGM:OMER PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:OMER Share Price ÷ Book Value per Share (both in USD)

= 12.21 ÷ -2.01

-6.07x

* Primary Listing of Omeros.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Omeros has negative assets, we can't compare the value of its assets to the US Pharmaceuticals industry average.

Next steps:

  1. Take a look at Omeros's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Omeros's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Pharmaceuticals industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Omeros's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Omeros has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Omeros expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
45.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Omeros expected to grow at an attractive rate?
  • Omeros's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Omeros's earnings growth is expected to exceed the United States of America market average.
  • Omeros's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:OMER Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:OMER Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 45.5%
NasdaqGM:OMER Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 26.6%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:OMER Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:OMER Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 424 68 120 3
2023-12-31 261 17 6 3
2022-12-31 162 -67 -71 4
2021-12-31 127 -67 -80 5
2020-12-31 119 -28 -75 4
2020-04-03
NasdaqGM:OMER Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 112 -60 -84
2019-09-30 100 -62 -79
2019-06-30 75 -91 -102
2019-03-31 50 -105 -121
2018-12-31 30 -104 -127
2018-09-30 22 -83 -120
2018-06-30 39 -58 -88
2018-03-31 54 -35 -68
2017-12-31 65 -36 -53
2017-09-30 64 -43 -57
2017-06-30 54 -43 -63
2017-03-31 46 -48 -61

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Omeros's earnings are expected to grow significantly at over 20% yearly.
  • Omeros's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:OMER Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Omeros Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:OMER Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 2.16 4.49 0.88 3.00
2023-12-31 0.10 2.50 -2.06 3.00
2022-12-31 -1.27 1.19 -3.88 4.00
2021-12-31 -1.48 0.10 -4.27 5.00
2020-12-31 -1.39 -1.09 -2.00 5.00
2020-04-03
NasdaqGM:OMER Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.71
2019-09-30 -1.60
2019-06-30 -2.08
2019-03-31 -2.48
2018-12-31 -2.61
2018-09-30 -2.48
2018-06-30 -1.84
2018-03-31 -1.47
2017-12-31 -1.17
2017-09-30 -1.28
2017-06-30 -1.46
2017-03-31 -1.47

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Omeros will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Omeros's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Omeros has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Omeros performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Omeros's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Omeros does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Omeros's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Omeros's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Omeros's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Omeros Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:OMER Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 111.81 -84.49 64.63 38.74
2019-09-30 100.41 -78.80 63.38 36.99
2019-06-30 75.16 -101.81 59.60 36.10
2019-03-31 50.06 -121.05 55.42 32.30
2018-12-31 29.87 -126.76 51.72 31.04
2018-09-30 21.61 -119.77 48.86 29.25
2018-06-30 38.66 -87.78 47.46 27.68
2018-03-31 54.16 -68.45 50.51 27.73
2017-12-31 64.83 -53.48 52.04 26.60
2017-09-30 63.97 -56.56 51.86 28.39
2017-06-30 53.60 -63.04 50.56 27.52
2017-03-31 46.46 -61.30 45.14 26.60
2016-12-31 41.62 -66.75 43.78 27.36
2016-09-30 35.39 -66.94 41.34 25.80
2016-06-30 27.36 -72.90 39.93 26.69
2016-03-31 20.54 -76.97 37.45 26.32
2015-12-31 13.51 -75.10 35.33 25.20
2015-09-30 7.01 -75.98 34.33 25.22
2015-06-30 3.97 -74.39 30.86 33.42
2015-03-31 0.83 -75.70 27.82 27.50
2014-12-31 0.54 -73.67 22.60 21.22
2014-09-30 0.53 -54.81 17.02 19.76
2014-06-30 0.51 -50.35 15.65 9.91
2014-03-31 0.61 -45.95 14.53 13.98
2013-12-31 1.60 -39.80 14.72 17.97
2013-09-30 3.01 -45.69 15.65 22.25
2013-06-30 4.24 -45.09 14.18 25.18

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Omeros has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Omeros has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Omeros improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Omeros's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Omeros has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Omeros's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Omeros's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Omeros is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Omeros's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Omeros's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Omeros has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Omeros Company Filings, last reported 3 months ago.

NasdaqGM:OMER Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -109.02 158.21 60.79
2019-09-30 -139.92 155.77 27.34
2019-06-30 -130.27 153.42 31.85
2019-03-31 -121.02 151.18 47.22
2018-12-31 -100.16 148.98 60.50
2018-09-30 -89.00 130.74 55.16
2018-06-30 -56.30 128.94 88.40
2018-03-31 -29.22 84.37 72.81
2017-12-31 -2.81 83.31 83.75
2017-09-30 9.21 82.25 86.81
2017-06-30 -54.85 81.20 29.67
2017-03-31 -48.11 80.18 33.65
2016-12-31 -37.45 79.19 45.33
2016-09-30 -22.77 70.48 47.44
2016-06-30 -49.00 70.03 21.24
2016-03-31 -40.74 50.04 13.24
2015-12-31 -26.23 49.56 28.26
2015-09-30 -9.00 28.55 35.00
2015-06-30 7.93 30.77 51.45
2015-03-31 21.85 32.93 70.06
2014-12-31 -42.65 32.45 6.89
2014-09-30 -26.59 32.54 21.78
2014-06-30 -10.61 32.37 37.46
2014-03-31 5.21 32.21 52.19
2013-12-31 -18.38 20.50 14.10
2013-09-30 -23.89 20.40 9.00
2013-06-30 -12.26 20.29 20.06
  • Omeros has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Omeros's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Omeros has less than a year of cash runway based on current free cash flow.
  • Omeros has less than a year of cash runway if free cash flow continues to grow at historical rates of 9.9% each year.
X
Financial health checks
We assess Omeros's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Omeros has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Omeros's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Omeros dividends.
If you bought $2,000 of Omeros shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Omeros's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Omeros's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:OMER Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1941 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:OMER Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Omeros has not reported any payouts.
  • Unable to verify if Omeros's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Omeros's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Omeros has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Omeros's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Omeros afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Omeros has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Omeros's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Greg Demopulos
COMPENSATION $4,740,339
AGE 60
TENURE AS CEO 25.8 years
CEO Bio

Dr. Gregory A. Demopulos, M.D., also known as Greg, founded Omeros Corporation in June 1994 and has been its Chairman of the Board, Chief Executive Officer and President since June 1994. Dr. Demopulos served as the Chief Financial Officer and Treasurer of Omeros Corporation from January 2009 to August 2013. He served as the Chief Medical Officer at Omeros Corporation from June 1994 to March 2010. He served as an Orthopedic Surgeon with specialized training in hand and microvascular surgery. Dr. Demopulos has been Director of Omeros Corporation and Onconome, Inc. since June 1994. He holds 18 patents in the life sciences with more than 50 additional patent applications. He was the recipient of numerous academic awards and honors. He left academic medicine to found Omeros in June 1994. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University. Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training in hand and microvascular surgery at Duke University.

CEO Compensation
  • Greg's compensation has increased whilst company is loss making.
  • Greg's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Omeros management team in years:

6.5
Average Tenure
60
Average Age
  • The average tenure for the Omeros management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Greg Demopulos

TITLE
Co-Founder
COMPENSATION
$5M
AGE
60
TENURE
25.8 yrs

Michael Jacobsen

TITLE
Chief Accounting Officer
COMPENSATION
$986K
AGE
61
TENURE
6.5 yrs

Pamela Palmer

TITLE
Co-Founder
AGE
56

George Gaitanaris

TITLE
Chief Scientific Officer & VP of Science
AGE
62
TENURE
8.3 yrs

Peter Cancelmo

TITLE
VP, General Counsel & Corporate Secretary
AGE
40
TENURE
0.8 yrs

Steve Whitaker

TITLE
VP of Clinical Development & Chief Medical Officer
AGE
63
TENURE
0.4 yrs

Cathy Melfi

TITLE
Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems
AGE
60
TENURE
7.5 yrs

Dan Kirby

TITLE
Chief Commercial Officer
AGE
47
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Omeros board of directors in years:

13.3
Average Tenure
68
Average Age
  • The average tenure for the Omeros board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Tom Cable

TITLE
Lead Independent Director
COMPENSATION
$167K
AGE
79

Greg Demopulos

TITLE
Co-Founder
COMPENSATION
$5M
AGE
60
TENURE
25.8 yrs

Ray Aspiri

TITLE
Independent Director
COMPENSATION
$160K
AGE
82
TENURE
25.3 yrs

Arnold Hanish

TITLE
Independent Director
COMPENSATION
$155K
AGE
71
TENURE
7.6 yrs

Lee Hood

TITLE
Independent Director
COMPENSATION
$147K
AGE
80
TENURE
19.1 yrs

Peter Demopulos

TITLE
Director
COMPENSATION
$140K
AGE
65
TENURE
25.3 yrs

Rajiv Shah

TITLE
Independent Director
COMPENSATION
$140K
AGE
47
TENURE
4.8 yrs

Tom Bumol

TITLE
Independent Director
AGE
65
TENURE
1.2 yrs

Kurt Zumwalt

TITLE
Director
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Omeros's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Omeros has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

The Omeros (NASDAQ:OMER) Share Price Has Gained 75% And Shareholders Are Hoping For More

Check out our latest analysis for Omeros Given that Omeros didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. … Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Simply Wall St -

Omeros (NASDAQ:OMER) May Be Weighed Down By Its Debt

NasdaqGM:OMER Historical Debt, July 30th 2019 How Strong Is Omeros's Balance Sheet? … This deficit isn't so bad because Omeros is worth US$751.1m, and thus could probably raise enough capital to shore up its balance sheet, if the need arose. … When we look at that and recall the liabilities on its balance sheet, relative to cash, it seems unwise to us for the company to have any debt.

Simply Wall St -

Is Omeros Corporation's (NASDAQ:OMER) CEO Salary Justified?

See our latest analysis for Omeros How Does Gregory Demopulos's Compensation Compare With Similar Sized Companies? … It would therefore appear that Omeros Corporation pays Gregory Demopulos more than the median CEO remuneration at companies of a similar size, in the same market. … We compared total CEO remuneration at Omeros Corporation with the amount paid at companies with a similar market capitalization.

Simply Wall St -

Do Insiders Own Lots Of Shares In Omeros Corporation (NASDAQ:OMER)?

With a market capitalization of US$882m, Omeros is a decent size, so it is probably on the radar of institutional investors. … See our latest analysis for Omeros NasdaqGM:OMER Ownership Summary, May 30th 2019 What Does The Institutional Ownership Tell Us About Omeros? … We can see that Omeros does have institutional investors; and they hold 47% of the stock.

Simply Wall St -

How Much is Omeros Corporation's (NASDAQ:OMER) CEO Getting Paid?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Gregory Demopulos's Compensation Compare With Similar Sized Companies. … According to our data, Omeros Corporation has a market capitalization of US$795m, and pays its CEO total annual compensation worth US$4.5m.

Simply Wall St -

What Type Of Shareholder Owns Omeros Corporation's (NASDAQ:OMER)?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Omeros is a smaller company with a market capitalization of US$609m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Why Omeros Corporation's (NASDAQ:OMER) CEO Pay Matters To You

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Gregory Demopulos's Compensation Compare With Similar Sized Companies. … Our data indicates that Omeros Corporation is worth US$684m, and total annual CEO compensation is US$4.5m.

Simply Wall St -

Loss-Making Omeros Corporation (NASDAQ:OMER) Expected To Breakeven

The US$901.62m market-cap posted a loss in its most recent financial year of -US$53.48m and a latest trailing-twelve-month loss of -US$68.45m leading to an even wider gap between loss and breakeven? … The most pressing concern for investors is OMER’s path to profitability – when will it breakeven

Simply Wall St -

What Are Analysts Saying About Omeros Corporation's (NASDAQ:OMER) Future?

Omeros Corporation's (NASDAQ:OMER) most recent earnings announcement in December 2017 showed company earnings became less negative compared to the previous year's level - great news for investors Below is a brief commentary on my key takeaways on how market analysts predict Omeros's earnings growth trajectory over the next few years and whether the future looks brighter. … The slope of this line is the rate of earnings growth, which in this case is 38.03%. … Future Earnings: How does OMER's growth rate compare to its peers and the wider market?

Simply Wall St -

Does Omeros Corporation's (NASDAQ:OMER) Past Performance Indicate A Stronger Future?

Below, I will assess OMER's latest performance announced on 31 December 2017 and weigh these figures against its longer term trend and industry movements. … View our latest analysis for Omeros How OMER fared against its long-term earnings performance and its industry I prefer to use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … This means although Omeros is presently running a loss, it may have benefited from industry tailwinds, moving earnings into a more favorable position.What does this mean?

Simply Wall St -

Company Info

Description

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company’s clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PDE10 (OMS824) which is in Phase II clinical trial for treating Huntington's disease and schizophrenia; PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company’s preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is based in Seattle, Washington.

Details
Name: Omeros Corporation
OMER
Exchange: NasdaqGM
Founded: 1994
$661,845,211
54,205,177
Website: http://www.omeros.com
Address: Omeros Corporation
201 Elliott Avenue West,
Seattle,
Washington, 98119,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM OMER Common Stock Nasdaq Global Market US USD 08. Oct 2009
DB 3O8 Common Stock Deutsche Boerse AG DE EUR 08. Oct 2009
LSE 0KBU Common Stock London Stock Exchange GB USD 08. Oct 2009
Number of employees
Current staff
Staff numbers
258
Omeros employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 06:11
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/03/04
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.